ArticleApplied microbiology and biotechnology2026
Rational development of an mRNA antibody cocktail with extended therapeutic window against ricin intoxication.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ricin, a highly toxic protein derived from Ricinus communis, is recognized as a biological threat due to its high toxicity and the absence of approved specific antidotes. Monoclonal antibodies (mAbs) represent an emergency therapeutic for ricin intoxication. However, the short therapeutic window of existing antibody administration significantly limits their effectiveness in post-exposure treatment. To address these limitations, we developed a novel strategy leveraging lipid nanoparticle (LNP) encapsulated-mRNA platform for toxin antibodies delivery in vivo, enabling a time-saving, cost-effective approach that extends the therapeutic window. We designed and characterized two mRNA-encoded antibodies targeting the A chain (RTA) and B chain (RTB) of ricin, termed mRNA-43RCA and mRNA-Sy1H3, respectively. Then, each LNP-encapsulated mRNA antibody was combined to formulate the final mRNA antibody cocktail, termed mRNA-cocktail-LNP. In vivo studies demonstrated that a single administration of mRNA-cocktail-LNP enabled the rapid production of neutralizing antibodies, which conferred protection in mice against a subsequent lethal-dose ricin challenge. Additionally, mRNA-cocktail-LNP exhibited a significantly extended circulating half-life compared to its protein-format antibody in mice, and a single prophylactic dose provided complete protection against lethal ricin challenge for at least 14 days post administration. More importantly, mRNA-cocktail-LNP conferred protection even when administered 10 h after lethal-dose ricin exposure, demonstrating an extended therapeutic window. Taken together, our results indicate that mRNA-cocktail-LNP represents a promising therapeutic candidate against ricin intoxication, highlighting the potential of mRNA-LNP platform as a universal strategy for developing antibody-based countermeasures against ricin and a broad spectrum of other biological threats. KEY POINTS: • An mRNA antibody cocktail (mRNA-cocktail-LNP) was designed to against RT and protect the mice from challenge with ricin both prophylactic and post-exposure treatments • mRNA-cocktail-LNP with a prolonged half-life compared to its protein format. • mRNA-cocktail-LNP significantly extended the limited therapeutic window to 10 h for ricin intoxication treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.